Amphiphilic Modulation of Glycosylated Antitumor Ether Lipids Results in a Potent Triamino Scaffold against Epithelial Cancer Cell Lines and BT474 Cancer Stem Cells

Journal of Medicinal Chemistry

Volumn 60, Issue 23, 2017, Pages 9724-9738

  Idowu, Temilolu ^a   Samadder, Pranati ^a   Arthur, Gilbert ^a   Schweizer, Frank ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 (12 AMINODODECYL) 2,6 DIAMINO 2,6 DIDEOXY BETA DEXTRO GLUCOPYRANOSIDE; 1 O HEXADECYL 2 O METHYL 3 O [2' AMINO 6' N (12 AMINODODECYL) 2',6' DIDEOXY BETA DEXTRO GLUCOPYRANOSIDE] SN GLYCEROL; 1 O HEXADECYL 2 O METHYL 3 O [2' AMINO 6' N (3 AMINOPROPYL) 2',6' DIDEOXY BETA DEXTRO GLUCOPYRANOSIDE] SN GLYCEROL; 1 O HEXADECYL 2 O METHYL 3 O [2' N (12 AMINODODECYL) 6' AMINO 2',6' DIDEOXY BETA DEXTRO GLUCOPYRANOSIDE] SN GLYCEROL; 1 O HEXADECYL 2 O METHYL 3 O [2' N (3 AMINOPROPYL) 6' AMINO 2',6' DIDEOXY BETA DEXTRO GLUCOPYRANOSIDE] SN GLYCEROL; 1 O HEXADECYL 2 O METHYL 3 O [6' N (12 N CHLORAMBUCIL DODECYL) 2',6' DIAMINO 2',6' DIDEOXY BETA DEXTRO GLUCOPYRANOSIDE] SN GLYCEROL; AMINE; AMPHOPHILE; ANTINEOPLASTIC AGENT; CASPASE; CHLORAMBUCIL; CISPLATIN; DOXORUBICIN; ETHER LIPID; MONOAMINE; SALINOMYCIN; UNCLASSIFIED DRUG; LIPID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BT-474 CELL LINE; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; EPITHELIAL CANCER CELL LINE; GLYCOSYLATION; HS 578T CELL LINE; HUMAN; HUMAN CELL; HYDROPHOBICITY; MDA-MB-231 CELL LINE; MDA-MB-453 CELL LINE; MDA-MB-468 CELL LINE; STRUCTURE ACTIVITY RELATION; TRIPLE NEGATIVE BREAST CANCER; AMINATION; CANCER STEM CELL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; EPITHELIUM CELL; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

AMINATION; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; EPITHELIAL CELLS; GLYCOSYLATION; HUMANS; LIPIDS; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 85033439702     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.7b01198     Document Type: Article

References (52)

1. Gottesman, M. M. Mechanism of cancer resistance Annu. Rev. Med. 2002, 53, 615-627 10.1146/annurev.med.53.082901.103929
2. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: Role of ATP-dependent transporters Nat. Rev. Cancer 2002, 2, 48-58 10.1038/nrc706
3. Longley, D. B.; Johnston, P. G. Molecular mechanisms of drug resistance J. Pathol. 2005, 205, 275-292 10.1002/path.1706
4. Magee, J. A.; Piskounova, E.; Morrison, S. J. Cancer stem cells: Impact, heterogeneity, and uncertainty Cancer Cell 2012, 21, 283-296 10.1016/j.ccr.2012.03.003
5. Clarke, M. F.; Dick, J. E.; Dirks, P. B.; Eaves, C. J.; Jamieson, C. H. M.; Jones, D. L.; Visvader, J.; Weissman, I. L.; Wahl, G. M. Cancer stem cells-Perspectives on current status and future directions: AACR workshop on cancer stem cells Cancer Res. 2006, 66, 9339-9344 10.1158/0008-5472.CAN-06-3126
6. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance Nat. Rev. Cancer 2005, 5, 275-284 10.1038/nrc1590
7. Samadder, P.; Bittman, R.; Byun, H.; Arthur, G. A glycosylated antitumor ether lipid kills cells via paraptosis-like cell death Biochem. Cell Biol. 2009, 87, 401-414 10.1139/O08-147
8. Samadder, P.; Byun, H. S.; Bittman, R.; Arthur, G. An active endocytosis pathway is required for the cytotoxic effects of glycosylated antitumor ether lipids Anticancer Res. 2011, 31, 3809-3818
9. Arthur, G.; Bittman, R. Glycosylated antitumor ether lipids: Activity and mechanism of action Anti-Cancer Agents Med. Chem. 2014, 14, 592-606 10.2174/1871520614666140309231144
10. Maltese, W. A.; Overmeyer, J. H. Non-apoptotic cell death associated with perturbations of macropinocytosis Front. Physiol. 2015, 6, 38 10.3389/fphys.2015.00038
11. Overmeyer, J. H.; Young, A. M.; Bhanot, H.; Maltese, W. A. A chalcone-related small molecule that induces methuosis, a novel form of non-apoptotic cell death, in glioblastoma cells Mol. Cancer 2011, 10, 69-79 10.1186/1476-4598-10-69
12. Samadder, P.; Xu, Y.; Schweizer, F.; Arthur, G. Cytotoxic properties of D-gluco-, D-galacto- and D-manno-configured 2-amino-2-deoxy-glycerolipids against epithelial cancer cell lines and BT-474 breast cancer stem cells Eur. J. Med. Chem. 2014, 78, 225-235 10.1016/j.ejmech.2014.03.057
13. Erukulla, R. K.; Zhou, X.; Samadder, P.; Arthur, G.; Bittman, R. Synthesis and evaluation of the antiproliferative effects of 1-O-hexadecyl-2-O-methyl-3-O-(2′-acetamido-2′-deoxy-β-D-glucopyranosyl)-sn-glycerol and 1-O-hexadecyl-2-O-methyl-3-O-(2′-amino-2′-deoxy-β-D-glucopyranosyl)-sn-glycerol on epithelial cancer J. Med. Chem. 1996, 39, 1545-1548 10.1021/jm950928f
14. Xu, Y.; Ogunsina, M.; Samadder, P.; Arthur, G.; Schweizer, F. Structural-activity relationships of glucosamine-derived glycerolipids ChemMedChem 2013, 8, 511-520 10.1002/cmdc.201200489
15. Petersen, N. H. T.; Olsen, O. D.; Groth-Pedersen, L.; Ellegaard, A.-M.; Bilgin, M.; Redmer, S.; Ostenfeld, M. S.; Ulanet, D.; Dovmark, T. H.; Lønborg, A.; Vindeløv, S. D.; Hanahan, D.; Arenz, C.; Ejsing, C. S.; Kirkegaard, T.; Rohde, M.; Nylandsted, J.; Jäättelä, M. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase Cancer Cell 2013, 24, 379-393 10.1016/j.ccr.2013.08.003
16. Utsugi, T.; Schroit, A. J.; Connor, J.; Bucana, C. D.; Fidler, I. J. Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes Cancer Res. 1991, 51, 3062-3066
17. Dobrzyńska, I.; Szachowicz-Petelska, B.; Sulkowski, S.; Figaszewski, Z. Changes in electric charge and phospholipids composition in human colorectal cancer cells Mol. Cell. Biochem. 2005, 276, 113-119 10.1007/s11010-005-3557-3
18. Yoon, W. H.; Park, H. D.; Lim, K.; Hwang, B. D. Effect of O-glycosylated mucin on invasion and metastasis of HM7 human colon cancer cells Biochem. Biophys. Res. Commun. 1996, 222, 694-699 10.1006/bbrc.1996.0806
19. Burdick, M. D.; Harris, A.; Reid, C. J.; Iwamura, T.; Hollingsworth, M. A. Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell lines J. Biol. Chem. 1997, 272, 24198-24202 10.1074/jbc.272.39.24198
20. Lee, H. S.; Park, C. B.; Kim, J. M.; Jang, S. A.; Park, I. Y.; Kim, M. S.; Cho, J. H.; Kim, S. C. Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide Cancer Lett. 2008, 271, 47-55 10.1016/j.canlet.2008.05.041
21. Kleeff, J.; Ishiwata, T.; Kumbasar, A.; Friess, H.; Büchler, M. W.; Lander, A. D.; Korc, M. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer J. Clin. Invest. 1998, 102, 1662-1673 10.1172/JCI4105
22. Schweizer, F. Cationic amphiphilic peptides with cancer-selective toxicity Eur. J. Pharmacol. 2009, 625, 190-194 10.1016/j.ejphar.2009.08.043
23. Zasloff, M. Antimicrobial peptides of multicellular organisms Nature 2002, 415, 389-395 10.1038/415389a
24. Hancock, R. E. W.; Sahl, H.-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies Nat. Biotechnol. 2006, 24, 1551-1557 10.1038/nbt1267
25. Giuliani, A.; Pirri, G.; Bozzi, A.; Di Giulio, A.; Aschi, M.; Rinaldi, A. C. Antimicrobial peptides: natural templates for synthetic membrane-active compounds Cell. Mol. Life Sci. 2008, 65, 2450-2460 10.1007/s00018-008-8188-x
26. Kozłowska, K.; Nowak, J.; Kwiatkowski, B.; Cichorek, M. ESR study of plasmatic membrane of the transplantable melanoma cells in relation to their biological properties Exp. Toxicol. Pathol. 1999, 51, 89-92 10.1016/S0940-2993(99)80074-8
27. Sok, M.; Sentjurc, M.; Schara, M. Membrane fluidity characteristics of human lung cancer Cancer Lett. 1999, 139, 215-220 10.1016/S0304-3835(99)00044-0
28. Arthur, G.; Schweizer, F.; Ogunsina, M. Synthetic glycosylated ether glycerolipids as anticancer agents. In Carbohydrates in Drug Design and Discovery; Jiménez-Barbero, J.; Cañada, F. J.; Martín-Santamaría, S., Eds.; RSC: Cambridge, UK, 2015; pp 151-179.
29. Ogunsina, M.; Pan, H.; Samadder, P.; Arthur, G.; Schweizer, F. Structure activity relationships of N-linked and diglycosylated glucosamine-based antitumor glycerolipids Molecules 2013, 18, 15288-15304 10.3390/molecules181215288
30. Ogunsina, M.; Samadder, P.; Idowu, T.; Arthur, G.; Schweizer, F. Design, synthesis and evaluation of cytotoxic properties of bisamino glucosylated antitumor ether lipids against cancer cells and cancer stem cells MedChemComm 2016, 7, 2100-2110 10.1039/C6MD00328A
31. Idowu, T.; Samadder, P.; Arthur, G.; Schweizer, F. Design, synthesis and antitumor properties of glycosylated antitumor ether lipid (GAEL)-chlorambucil-hybrids Chem. Phys. Lipids 2016, 194, 139-148 10.1016/j.chemphyslip.2015.07.003
32. Ogunsina, M.; Samadder, P.; Idowu, T.; Arthur, G.; Schweizer, F. Replacing D-glucosamine with its L-enantiomer in glycosylated antitumor ether lipids (GAELs) retains cytotoxic effects against epithelial cancer cells and cancer stem cells J. Med. Chem. 2017, 60, 2142-2147 10.1021/acs.jmedchem.6b01773
33. Richter, M. F.; Drown, B. S.; Riley, A. P.; Garcia, A.; Shirai, T.; Svec, R. L.; Hergenrother, P. J. Predictive compound accumulation rules yield a broad-spectrum antibiotic Nature 2017, 545, 299-304 10.1038/nature22308
34. Findlay, B.; Zhanel, G. G.; Schweizer, F. Cationic amphiphiles, a new generation of antimicrobials inspired by the natural antimicrobial peptide scaffold Antimicrob. Agents Chemother. 2010, 54, 4049-4058 10.1128/AAC.00530-10
35. Shou, J.; Massarweh, S.; Osborne, C. K.; Wakeling, A. E.; Ali, S.; Weiss, H.; Schiff, R. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J. Natl. Cancer Inst. 2004, 96, 926-935 10.1093/jnci/djh166
36. Kim, K.; Lee, E.; Lee, J.; Bae, J.; Korea Breast Cancer Society Clinicopathologic signature of TNBC patients with good prognosis Cancer Res. 2009, 69, 4065-4065 10.1158/0008-5472.SABCS-09-4065
37. Zobalova, R.; Stantic, M.; Stapelberg, M.; Prokopova, K.; Dong, L.; Truksa, J.; Neuzil, J. Drugs that kill cancer stem-like cells. In Cancer Stem Cells Theories and Practice; Shosta, S., Ed.; InTech: Zagreb, Croatia, 2011; pp 361-378.
38. Ginestier, C.; Hur, M. H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C. G.; Liu, S.; Schott, A.; Hayes, D.; Birnbaum, D.; Wicha, M. S.; Dontu, G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome Cell Stem Cell 2007, 1, 555-567 10.1016/j.stem.2007.08.014
39. Charafe-Jauffret, E.; Ginestier, C.; Iovino, F.; Wicinski, J.; Cervera, N.; Finetti, P.; Hur, M.-H.; Diebel, M. E.; Monville, F.; Dutcher, J.; Brown, M.; Viens, P.; Xerri, L.; Bertucci, F.; Stassi, G.; Dontu, G.; Birnbaum, D.; Wicha, M. S. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature Cancer Res. 2009, 69, 1302-1313 10.1158/0008-5472.CAN-08-2741
40. Croker, A. K.; Goodale, D.; Chu, J.; Postenka, C.; Hedley, B. D.; Hess, D. A.; Allan, A. L. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability J. Cell. Mol. Med. 2009, 13, 2236-2252 10.1111/j.1582-4934.2008.00455.x
41. Li, X.; Lewis, M. T.; Huang, J.; Gutierrez, C.; Osborne, C. K.; Wu, M.-F.; Hilsenbeck, S. G.; Pavlick, A.; Zhang, X.; Chamness, G. C.; Wong, H.; Rosen, J.; Chang, J. C. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy J. Natl. Cancer Inst. 2008, 100, 672-679 10.1093/jnci/djn123
42. Henkels, K. M.; Turchi, J. J. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines Cancer Res. 1999, 59, 3077-3083
43. Huczynski, A. Salinomycin: A new cancer drug candidate Chem. Biol. Drug Des. 2012, 79, 235-238 10.1111/j.1747-0285.2011.01287.x
44. Gupta, P. B.; Onder, T. T.; Jiang, G.; Tao, K.; Kuperwasser, C.; Weinberg, R. A.; Lander, E. S. Identification of selective inhibitors of cancer stem cells by high-throughput screening Cell 2009, 138, 645-659 10.1016/j.cell.2009.06.034
45. Caserta, T. M.; Smith, A. N.; Gultice, A. D.; Reedy, M. A.; Brown, T. L. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties Apoptosis 2003, 8, 345-352 10.1023/A:1024116916932
46. Doroshow, J. H. Role of hydrogen peroxide and hydroxyl radical formation in the killing of ehrlich tumor cells by anticancer quinones Proc. Natl. Acad. Sci. U. S. A. 1986, 83, 4514-4518 10.1073/pnas.83.12.4514
47. Thorn, C. F.; Oshiro, C.; Marsh, S.; Hernandez-Boussard, T.; McLeod, H.; Klein, T. E.; Altman, R. B. Doxorubicin pathways: Pharmacodynamics and adverse effects Pharmacogenet. Genomics 2011, 21, 440-446 10.1097/FPC.0b013e32833ffb56
48. MacFarlane, M. Cell death pathways-potential therapeutic targets Xenobiotica 2009, 39, 616-624 10.1080/00498250903137990
49. Markovits, J.; Roques, B. P.; Le Pecq, J.-B. Ethidium dimer: A new reagent for the fluorimetric determination of nucleic acids Anal. Biochem. 1979, 94, 259-264 10.1016/0003-2697(79)90357-9
50. Visvader, J. E.; Lindeman, G. J. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions Nat. Rev. Cancer 2008, 8, 755-768 10.1038/nrc2499
51. Kreso, A.; Dick, J. E. Evolution of the cancer stem cell model Cell Stem Cell 2014, 14, 275-291 10.1016/j.stem.2014.02.006
52. Lyu, Y.; Yang, X.; Goswami, S.; Gorityala, B. K.; Idowu, T.; Domalaon, R.; Zhanel, G. G.; Shan, A.; Schweizer, F. Amphiphilic tobramycin-lysine conjugates sensitize multidrug resistant gram-negative bacteria to rifampicin and minocycline J. Med. Chem. 2017, 60, 3684-3702 10.1021/acs.jmedchem.6b01742